Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;24(9_suppl):340S-349S.
doi: 10.1177/1076029618812955. Epub 2018 Nov 28.

Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide

Eduardo Ramacciotti  1   2   3 , Valéria Cristina Resende Aguiar  2 , Valter Castelli Júnior  1 , Ivan Benaducce Casella  4 , Antonio Eduardo Zerati  4 , Jawed Fareed  3
Affiliations
Review

Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide

Eduardo Ramacciotti et al. Clin Appl Thromb Hemost. 2018 Dec.

Abstract

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. This practical guide aims to help Latin America clinicians understand edoxaban, its proper indication and its use for the appropriate patients with VTE.

Keywords: edoxaban; non-vitamin K antagonist oral anticoagulants; oral anticoagulants; venous thromboembolism; vitamin K antagonists.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Chemical structure of edoxaban: N-(5-chloropyridin-2-yl)-N′-[(1S,2R,4S)-4-(N, N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazol-o[5,4-c]pyridine-2-carboxamido)-cyclohexyl] ethanediamide p-toluenesulfonate monohydrate. Adapted from Furugohri, T. et al.
Figure 2.
Figure 2.
Geometric mean plasma concentrations of edoxaban (ng/mL) after oral dosing. Note that the x-axes are not continuous. Data from the single-administration study. Adapted from Ogata, K. et al.
Figure 3.
Figure 3.
Practical guide for the treatment of special populations with edoxaban. Adapted from Brazilian label recommendations.
See this image and copyright information in PMC

References

    1. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ., 3rd Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6):761–768. - PubMed
    1. Ceresetto JM. Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care. Clinics (Sao Paulo). 2016;71(1):36–46. - PMC - PubMed
    1. Wells P, Anderson D. The diagnosis and treatment of venous thromboembolism. Hematology Am Soc Hematol Educ Program. 2013;2013:457–463. - PubMed
    1. Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. Plos One. 2015;10(12):e0144856. - PMC - PubMed
    1. Comerota AJ, Ramacciotti E. A Comprehensive overview of direct oral anticoagulants for the management of venous thromboembolism. Am J Med Sci. 2016;352(1):92–106. - PubMed

LinkOut - more resources